Genomic alterations of TP53 were most common in the TMB-H with MSS group in endometrial (61.1%) and ovarian (82.8%) cancers, whereas the rate was 12.0% in cervical cancer (usually human papillomavirus [HPV], which relates to the impairment of TP53 by the ubiquitin–proteasome pathway). This evidence concerns the gene TP53 and cervical carcinoma.